Skip to main content

Table 1 Patients’ characteristics at baseline

From: Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study

Variables

Categories

Total

n (%)

Total

 

8230

Gender

Male

6013 (73.1)

Age at baseline (years)

18–24

610 (7.4)

25–34

2681 (32.6)

35–44

3054 (37.1)

45–54

1337 (16.3)

≥55

548 (6.7)

Mean (SD)

38.4 (10.1)

Country of origin

Italy

6539 (80.7)

Others

1561 (19.3)

Year of enrolment

2000–2002

2077 (25.2)

2003–2006

2544 (30.9)

2007–2009

1943 (23.6)

2010–2012

1666 (20.2)

IDU

Yes

4516 (35.8)

HBV/HCV co-infection

Yes

2430 (29.5)

CD4 cell count

0–49

523 (6.8)

50–99

516 (6.7)

100–199

1007 (13.0)

200–349

1733 (22.4)

350–499

1659 (21.5)

≥500

2296 (29.7)

 

Mean (SD)

395.5 (277.6)

CD4/CD8 ratio

<0.3

2733 (40.3)

0.3–0.45

1356 (20.0)

≥0.45

2689 (39.7)

Mean (SD)

0.4 (0.3)

HIV-RNA log10

Mean (SD)

4.6 (1.0)

Late presentation

Yes

4516 (58.6)

Advanced late presentation

Yes

3135 (40.7)

Lymphocytes

Mean (SD)

1962.4 (896.5)

Platelets

Mean (SD)

220351.6 (80150.0)

Neutrophils

Mean (SD)

2910.9 (1456.2)

PLR

<100

2675 (39.1)

100–200

3132 (45.7)

≥200

1043 (15.2)

Mean (SD)

139.1 (100.8)

NLR

<2

3826 (71.8)

2.4

1200 (22.5)

≥4

305 (5.7)

Mean (SD)

1.8 (1.5)

  1. Late presentation refers to persons diagnosed with HIV with a CD4 cell count below 350/mm3 or with an AIDS defining event regardless of the CD4 cell count in the 6 months following HIV diagnosis. Late presentation with HIV advanced disease refers to persons diagnosed with HIV with a CD4 cell count below 200/mm3 or with an AIDS defining event, regardless of CD4 cell count in the 6 months following HIV
  2. Abbreviations: SD standard deviation, IDU intravenous drug use, HBV Hepatitis B viruses, HCV Hepatitis C viruses, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratio